


**ESCALATION PHASE**  
**N=20**

A

Dose Level	Palbociclib	Taselisib	Estimated No of patients
-1	75mg once daily 21-days-on and 7-days-off treatment	2mg once daily 21-days-on and 7-days-off treatment	3 + 3
1	100mg once daily 21-days-on and 7-days-off treatment	2mg once daily 21-days-on and 7-days-off treatment	3 + 3
2	100mg once daily 21-days-on and 7-days-off treatment	4mg once daily 21-days-on and 7-days-off treatment	3 + 3
3	125mg once daily 21-days-on and 7-days-off treatment	2mg once daily 21-days-on and 7-days-off treatment	3 + 3
4	125mg once daily 21-days-on and 7-days-off treatment	2mg once daily Continuously	3 + 3

B



Level 1 (N=4): 2 colorectal carcinoma, 1 triple-negative breast carcinoma and 1 cervical carcinoma.

Level 2 (N=3): 1 colorectal carcinoma, 1 mucosal melanoma and 1 leiomyosarcoma of retroperitoneum.

Level 3 (N=7): 1 colorectal carcinoma, 1 cholangiocarcinoma, 1 epithelioid mesothelioma, 1 non-small cell lung carcinoma, 1 oesophageal carcinoma, 1 metastatic Leydig cell tumor and 1 conjunctival melanoma.

Level 4 (N=6): 2 ER+ve/HER2-ve breast carcinoma, 1 ER+ve/HER+ve breast carcinoma, 2 colorectal carcinoma and 1 basaloid squamous cell carcinoma of oropharynx.

**Supplementary Figure 1. Escalation phase dose levels and final recruitment.**

- A) Part A dose levels with combination doses schedules and estimated number of patients to be treated per level.
- B) Part A final patient recruitment and dose-limiting toxicities observed in each dose level. Below tumor types treated in each dose escalation level.